Mckesson CORP 8-K filings

McKesson Corporation's annual shareholder meeting saw the re-election of all director nominees and the ratification of Deloitte & Touche LLP as independent auditors, with advisory approval for executive compensation.

McKesson Corporation announces the retirement of its Chief Strategy and Business Development Officer and appoints a successor, alongside disclosures of maturing debt.

McKesson Corporation announces a $2.25 billion senior secured term B loan facility due 2032, amending its existing credit agreement.

McKesson Corporation announced robust fourth quarter and full fiscal year 2026 results, exceeding long-term growth targets, and provided positive guidance for fiscal year 2027.

McKesson Corporation has entered into a new $5 billion revolving credit facility, replacing its existing credit lines and extending its maturity to April 2031.

McKesson Medical-Surgical Top Holdings Inc. entered into a $2.0 billion senior secured credit agreement to support working capital and general corporate purposes.

McKesson Corporation announced its fourth quarter fiscal 2026 earnings release date, upcoming conference participation, and reaffirmed its full-year fiscal 2026 outlook.

McKesson Corporation announced the retirement of CFO Britt J. Vitalone and the appointment of Kenny K. Cheung as his successor, effective May 29, 2026.

McKesson Corporation announced record second quarter revenues and a significant increase in adjusted earnings per diluted share, leading to an upward revision of its full-year fiscal 2026 adjusted EPS guidance.

McKesson Corporation raised its Fiscal 2026 adjusted earnings per diluted share guidance and increased its long-term growth targets, highlighting strategic priorities at its Investor Day.

McKesson Corporation announced a significant organizational restructuring, realigning its financial reporting into four new segments and entering an agreement to sell its Norwegian operations.

McKesson Corporation reported strong first-quarter fiscal 2026 results with record revenue growth and raised its full-year adjusted earnings per diluted share guidance.

McKesson Corporation announced the results of its Annual Meeting of Shareholders held on July 30, 2025, confirming the election of all director nominees, the ratification of Deloitte & Touche LLP as independent auditors, and the advisory approval of executive compensation.

McKesson Corporation has increased its Adjusted Earnings per Diluted Share guidance for Fiscal Year 2026, signaling a positive financial outlook ahead of scheduled investor and analyst meetings.

McKesson Corporation has successfully completed a $2 billion multi-tranche senior notes offering, with proceeds earmarked for the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC.

McKesson Corporation announces strong fiscal 2025 results with revenue growth and adjusted earnings per diluted share increase, alongside plans to separate its Medical-Surgical Solutions segment.

McKesson Corporation announced an 18% increase in consolidated revenues for the third quarter of fiscal year 2025 and raised its full-year adjusted earnings per diluted share guidance.

McKesson Corporation announced robust third-quarter results, driven by revenue growth and strategic initiatives, leading to an increased and narrowed adjusted earnings per diluted share guidance for fiscal year 2025.

McKesson Corporation announced a 21% increase in revenue and a 13% increase in adjusted earnings per diluted share for the second quarter of fiscal year 2025, leading to an increased full-year adjusted EPS guidance.

McKesson Corporation has successfully priced and issued $500 million in new debt securities to refinance existing obligations.

McKesson Corporation reaffirmed its full-year fiscal 2025 adjusted earnings per diluted share guidance and provided second-quarter fiscal 2025 earnings expectations during a presentation at the Wells Fargo 2024 Healthcare Conference.

McKesson Corporation has agreed to acquire a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion in cash.

McKesson Corporation announced a 6% increase in first-quarter revenue and raised its full-year adjusted earnings per diluted share guidance, alongside a 15% dividend increase and a $4 billion share repurchase program expansion.

McKesson Corporation held its annual shareholder meeting on July 31, 2024, where directors were elected, the appointment of the auditor was ratified, executive compensation was approved, and an amendment to the company's charter was passed.

McKesson Corporation has appointed Deborah Dunsire to its Board of Directors, while Linda Mantia and Susan Salka will not seek re-election at the upcoming annual meeting.

McKesson Corporation announced its fourth quarter and full-year fiscal 2024 results, highlighting revenue growth and providing a positive outlook for fiscal year 2025.

McKesson Corporation announced a 15% increase in third-quarter revenue and raised its full-year adjusted earnings per diluted share guidance.